Kim M, Lee J-O, Koh J, Kim TM, Lee JY, Jeon YK, Keam B, Kim D-W, Lee JS, Heo DS. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. haematol [Internet]. 2021Aug.1 [cited 2024Apr.20];106(8):2277-80. Available from: https://haematologica.org/article/view/haematol.2021.278301